OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr McLellan on the Association Between A Skin Bacterium and Severe Acute Radiation Dermatitis

October 9th 2023

Beth N. McLellan, MD, discusses the use of a low-cost, topical treatment to prevent severe cases of acute radiation dermatitis potentially caused by the skin bacterium Staphylococcus aureus in breast cancer.

Dr Danilov on the Investigation of BTK Degraders in CLL

October 8th 2023

Alexey Danilov, MD, PhD, discusses the investigation of BTK degraders in the treatment of chronic lymphocytic leukemia.

Dr Woyach on the Prevalence of Mutations in Previously Treated Patients With CLL

October 8th 2023

Jennifer A Woyach, MD, discusses the prevalence of recurrent genomic alterations in apoptotic machinery in patients with previously treated chronic lymphocytic leukemia who were refractory to B-cell receptor pathway inhibitors.

Dr Melenhorst on the Evolving Understanding of CAR T-Cell Therapies in CLL

October 8th 2023

Jan Joseph Melenhorst, PhD, discusses the evolving understanding of the use of CAR T-cell therapies in the treatment of patients with chronic lymphocytic leukemia.

Dr Shadman on Zanubrutinib in CLL/SLL Intolerant to Prior BTK Inhibitors

October 8th 2023

Mazyar Shadman, MD, MPH, discusses preliminary long-term findings from the evaluation of zanubrutinib in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were intolerant to ibrutinib and/or acalabrutinib.

Dr Feigin on the Effect of Benzodiazepines on Survival Outcomes in Pancreatic Cancer

October 7th 2023

Michael Feigin, PhD, discusses data from a retrospective study investigating the association between benzodiazepines and survival outcomes in patients with pancreatic cancer.

Dr Platzbecker on the COMMANDS Trial in Lower-Risk MDS With Anemia

October 7th 2023

Uwe Platzbecker, MD, discusses key findings from the phase 3 COMMANDS trial with luspatercept in patients with lower-risk myelodysplastic syndrome with anemia, as well as the clinical implications of FDA approval of luspatercept for patients in this population.

Dr Jeselsohn on Enrollment Criteria For the VERITAC-2 Trial in ER+ Breast Cancer

October 7th 2023

Rinath M. Jeselsohn, MD, discusses enrollment criteria for the phase 3 VERITAC-2 trial, as well as the potential clinical implications of this research for patients with advanced estrogen receptor–positive/HER2-negative metastatic breast cancer.

Dr Berdeja on the Current Landscape of BCMA-Directed Therapies in Multiple Myeloma

October 7th 2023

Jesus Berdeja, MD, discusses the BCMA-directed CAR T-cell therapies and bispecific antibodies available for patients with multiple myeloma.

Dr Harpole on the Design of an Exploratory Analysis of the AEGEAN Trial in NSCLC

October 7th 2023

David Harpole, MD, discusses on the rationale and design of an exploratory analysis of the phase 3 AEGEAN trial in patients with EGFR-mutated non–small cell lung cancer, which he presented at the 2023 IASLC World Conference on Lung Cancer.

Dr Haffty on the Rationale for Investigating Preoperative Radiation Boosts in Breast Cancer

October 7th 2023

Bruce Haffty, MD, MS, discusses the rationale for launching a clinical trial to assess the feasibility of preoperative radiation boost in patients with breast cancer.

Dr Choueiri on the Benefit of Ongoing Investigations in Metastatic RCC

October 7th 2023

Toni K. Choueiri, MD, discusses the benefit of ongoing investigations in metastatic, advanced renal cell carcinoma.

Dr. Moustafa on Clinical Implications of the BRUIN Trial of Pirtobrutinib in MCL

October 6th 2023

Muhamad Alhaj Moustafa, MD, MS, has improved the treatment of patients with mantle cell lymphoma, and the role that this agent has in the current treatment landscape.

Dr Parrondo on the Clinical Benefit of Momelotinib on Anemia in Myelofibrosis

October 6th 2023

Ricardo D. Parrondo, MD, discusses the clinical benefit seen with momelotinib in anemic myelofibrosis, and where it fits into the current treatment paradigm in this disease landscape.

Dr Aerts on the Rationale for the DENIM Trial in Mesothelioma

October 5th 2023

Joachim G. J. V. Aerts, MD, PhD, discusses the rationale for conducting the phase 3 DENIM trial in patients with mesothelioma, highlighting the importance of focusing investigational efforts onto the dendritic cells.

Dr Usmani on Approaching Treatment Decisions in High-Risk Multiple Myeloma

October 5th 2023

Saad Z. Usmani, MD, MBA, FACP, discusses the complexity of approaching frontline treatment decisions in patients with high-risk multiple myeloma.

Dr Kahl on Ongoing and Planned Investigations Within the Landscape of MCL

October 5th 2023

Brad S. Kahl, MD, discusses ongoing and planned investigations within the landscape of mantle cell lymphoma.

Dr Ikegawa on An Analysis of Rapidly Manufactured Durcabtagene Autoleucel in R/R Multiple Myeloma

October 5th 2023

Shuntaro Ikegawa, MD, PhD, discusses results from a correlative analysis of an ongoing phase 1 trial evaluating the use of a novel T-Charge rapid manufacturing platform for the production of durcabtagene autoleucel CAR T-cells in multiple myeloma.

Dr Haffty on the Feasibility of Preoperative Radiation Boost in Breast Cancer

October 5th 2023

Bruce Haffty, MD, MS, discusses the feasibility of utilizing preoperative radiation boost in patients with breast cancer based on initial results from a phase 2 trial.

Dr Rahimi on Escalating Preoperative, Single-Fraction Ablative Radiation in HR-Positive Breast Cancer

October 4th 2023

Asal Rahimi, MD, MS, discusses initial efficacy results from the expanded cohort of a phase 1 dose-escalation study (NCT04040569) evaluating pre-operative, single fraction stereotactic ablative radiation in early-stage, hormone receptor–positive breast cancer.